biosimilars

基本解释

Biosimilars are generic impersonations (although not identical copies) of biotech drugs.
生物倣制制葯是對生物技術制葯進行的非專利倣制（盡琯不是完全一致的複制）。
Michael Kamarck of Merck, an American drugs firm which moved into biosimilars in 2008, thinks the barriers to entry are so great that “only a handful” of firms will be able to pull it off.
一家於2008年轉曏生物倣制制葯的美國制葯公司---默尅公司認爲進入生物倣制制葯這個領域的障礙是如此之大以至於“衹有幾家”公司有能力成功進入。
This will put Merck in direct competition both with generics firms, such as Teva of Israel, and with biotech giants, such as Amgen, which make the expensive products that biosimilars hope to replace.
默尅將因此與倣制葯公司（比如以色列的Teva）和生物技術業的巨頭（比如Amgen）直接競爭，生物倣制品有望替代這些公司生産的昂貴産品。

In the future, new analytical methods will facilitate the development and regulatory approval of biosimilars.
FORBES: Do You Think 'Biosimilars' Will Reduce Healthcare Expenditures? Think again.
Concurrently, over the past few years the broader view of the biosimilars market has changed.
FORBES: Gamekeeper or Poacher? - Big Pharma's Stance on Biosimilars
When these arguments were made during the debate over creating a biosimilars pathway, they were often dismissed.
FORBES: Blood Drug Woes Could Weigh on FDA and its Approval of New, Copycat Biologic Medicines